What 10 Analyst Ratings Have To Say About Sage Therapeutics
Portfolio Pulse from Benzinga Insights
Sage Therapeutics (NASDAQ:SAGE) has received a mix of bullish and indifferent analyst ratings in the last quarter, with no bearish ratings. The average 12-month price target for the company has increased by 6.32% from the previous average of $52.67 to $56.00.
July 27, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sage Therapeutics has received mixed analyst ratings, with an increased 12-month price target. This could potentially influence investor sentiment.
Analyst ratings can significantly influence investor sentiment and stock prices. The mixed ratings for Sage Therapeutics, along with an increased 12-month price target, suggest a potentially positive short-term impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100